TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A phase II trial of 18 breast cancer survivors found improved self-reported cognitive symptoms and fatigue after participants took oxaloacetate for eight weeks. The findings are preliminary: the study was small and does not establish that the supplement caused the improvements or works for other patients.
A small clinical trial led by researchers at UCLA Health Jonsson Comprehensive Cancer Center found that breast cancer survivors reported less brain fog and fatigue after taking oxaloacetate for eight weeks. The phase II study included 18 women, and its encouraging results are preliminary: larger controlled trials are needed to determine whether the supplement is effective and safe for broader use.
Participants were women diagnosed with early-stage breast cancer one to five years earlier, all of whom reported substantial cognitive difficulties when they joined the study. Their average age was about 50. Most had received chemotherapy, and nearly 90% were still receiving endocrine therapy during the trial. Each was instructed to take 500 milligrams of oxaloacetate twice daily for eight weeks.
Sixteen of the 18 participants completed the study. Those who finished reported improvements in memory, concentration and other cognitive symptoms. On the trial’s main measure of perceived cognitive impairment, the group’s average score rose from 29.1 before supplementation to 55.5 after eight weeks; researchers said the latter score fell in the range considered normal rather than impaired. Reported improvements were apparent by week four and generally grew over the treatment period.
Participants also reported less fatigue and better physical functioning. Standardized tests indicated improvement in processing speed and executive function, which includes skills used to plan, focus and manage tasks. The researchers monitored possible side effects; the available report says oxaloacetate was generally well tolerated and identifies digestive complaints, including indigestion, as the most frequently reported side effects.
A Possible Option for Persistent Symptoms
Memory problems, difficulty concentrating and exhaustion can interfere with work and everyday activities after cancer treatment. The study addresses a need identified by its researchers: few established treatments are available for cancer-related cognitive impairment, which may continue after active treatment ends. A supplement that could help would matter to survivors, but this trial does not establish oxaloacetate as a treatment or show that patients should start taking it.
The findings are a signal for further research, not a measure of how well the supplement would work in routine care. The trial was small, lasted only eight weeks and, in the report provided, does not include a comparison group receiving a placebo. Without a stronger comparison, changes over time cannot be confidently attributed to the supplement. The reported improvement therefore needs confirmation in larger studies.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
Blueair Blue Pure 511i Max Smart Air Purifier
Philips Sonicare ProtectiveClean 5300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Oxaloacetate
Persistent cognitive difficulties after breast cancer are often called “chemo brain” or “brain fog,” but chemotherapy is not necessarily the only factor. The source report says researchers estimate that roughly 15% to 25% of people experience ongoing problems with memory, concentration or other thinking abilities after breast cancer diagnosis and treatment. Cancer itself, chemotherapy, endocrine therapy, inflammation and hormonal changes may all contribute.
Oxaloacetate is a molecule that occurs naturally in the body and has a role in cellular energy production. The UCLA team was interested in its relationship to energy processes and glutamate, a chemical involved in communication between nerve cells. The researchers proposed that inflammation and disruptions in these processes may contribute to cognitive symptoms. The trial tested whether supplementation was associated with changes in symptoms; it does not establish that those proposed mechanisms explain the results.
The results were published in JCO Oncology Advances, according to the original report. The researchers assessed participants with self-reported questionnaires and standardized cognitive tests, as well as tracking fatigue, sleep, mood and other measures.
““Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it.””
— Dr. Patricia Ganz, the study’s first author and a professor at UCLA
Small Trial Leaves Key Questions
The findings cannot show whether oxaloacetate caused the improvements. The study enrolled only 18 participants, with 16 completing all eight weeks; the source report does not describe a placebo control or blinding. The reported score change is specific to this group and assessment, and should not be taken as proof that all survivors would improve or that symptoms would remain better after supplementation ended.
Further questions include whether the results can be replicated in a larger, more diverse group; how long any benefits might last; and which patients, if any, might benefit. The available report does not provide detailed side-effect rates or longer-term safety results. It also does not establish an appropriate use outside a clinical study. People considering supplements should discuss them with a qualified health professional, particularly while receiving cancer treatment or taking other medicines.
Larger Studies Needed to Confirm Results
The next step is further clinical research, including larger trials that can test whether the reported changes are attributable to oxaloacetate and assess safety over a longer period. The source report says larger studies are needed but does not provide a timeline, details of a planned follow-up trial or a date for new results.
For now, the findings support continued investigation rather than a change in standard care. Survivors experiencing cognitive difficulties or fatigue can raise those symptoms with their care team; the trial does not establish oxaloacetate as a proven remedy.
Key Questions
What did the oxaloacetate study find?
In a small trial, breast cancer survivors who completed eight weeks of supplementation reported improved cognitive symptoms and less fatigue. Tests also showed improvements in processing speed and executive function, but the results need confirmation.
How many people took part?
The phase II trial enrolled 18 women; 16 completed the eight-week study. All had substantial cognitive difficulties when they enrolled.
Does the study prove oxaloacetate clears brain fog?
No. The trial was small, and the report does not describe a placebo comparison. It provides preliminary evidence, not proof that the supplement caused the changes or will help other survivors.
Was oxaloacetate well tolerated?
The report says it was generally well tolerated over eight weeks, with digestive problems such as indigestion among the most frequently reported side effects. It does not establish longer-term safety.
Should cancer survivors take the supplement?
The study does not establish oxaloacetate as a proven treatment or recommend its use. Anyone considering a supplement should discuss it with a qualified health professional, especially during cancer treatment or while taking other medicines.
Source: sciencedaily.com
